JP2002507564A - βアミロイドタンパク質を減少させるための方法 - Google Patents

βアミロイドタンパク質を減少させるための方法

Info

Publication number
JP2002507564A
JP2002507564A JP2000537538A JP2000537538A JP2002507564A JP 2002507564 A JP2002507564 A JP 2002507564A JP 2000537538 A JP2000537538 A JP 2000537538A JP 2000537538 A JP2000537538 A JP 2000537538A JP 2002507564 A JP2002507564 A JP 2002507564A
Authority
JP
Japan
Prior art keywords
composition
cholesterol
individual
production
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000537538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002507564A5 (https=
Inventor
ブルース エイ． ヤンクナー，
フィリップ ナデュー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2002507564A publication Critical patent/JP2002507564A/ja
Publication of JP2002507564A5 publication Critical patent/JP2002507564A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000537538A 1998-03-23 1999-03-23 βアミロイドタンパク質を減少させるための方法 Pending JP2002507564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/046,235 1998-03-23
US09/046,235 US6080778A (en) 1998-03-23 1998-03-23 Methods for decreasing beta amyloid protein
PCT/US1999/006396 WO1999048488A2 (en) 1998-03-23 1999-03-23 Methods for decreasing beta amyloid protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009274999A Division JP2010047616A (ja) 1998-03-23 2009-12-02 βアミロイドタンパク質を減少させるための方法

Publications (2)

Publication Number Publication Date
JP2002507564A true JP2002507564A (ja) 2002-03-12
JP2002507564A5 JP2002507564A5 (https=) 2006-04-06

Family

ID=21942345

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000537538A Pending JP2002507564A (ja) 1998-03-23 1999-03-23 βアミロイドタンパク質を減少させるための方法
JP2009274999A Pending JP2010047616A (ja) 1998-03-23 2009-12-02 βアミロイドタンパク質を減少させるための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009274999A Pending JP2010047616A (ja) 1998-03-23 2009-12-02 βアミロイドタンパク質を減少させるための方法

Country Status (6)

Country Link
US (5) US6080778A (https=)
EP (1) EP1063980A2 (https=)
JP (2) JP2002507564A (https=)
AU (1) AU759257B2 (https=)
CA (1) CA2324999A1 (https=)
WO (1) WO1999048488A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150107938A (ko) * 2014-03-13 2015-09-24 주식회사 하이폭시 차전자피를 포함하는 기억력 및 인지기능 증진용 조성물

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
EP1133699A1 (en) * 1998-11-25 2001-09-19 Scios Inc. Prevention and treatment of amyloid-associated disorders
US20020055529A1 (en) * 1998-12-02 2002-05-09 Bisgaier Charles Larry Method for treating alzheimer's disease
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
JP2003523948A (ja) * 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
AR027878A1 (es) * 1999-11-05 2003-04-16 Wyeth Corp Metodos para identificar y utilizar compuestos inhibidores de amiloides
AU2001233299A1 (en) * 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US7439052B2 (en) * 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da) 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2437480A1 (en) * 2001-02-05 2002-08-15 Andrx Corporation Method of treating amyloid .beta. precursor disorder
US20020173535A1 (en) * 2001-02-07 2002-11-21 Renshaw Perry F. Cholesterol-lowering agents as treatment for psychological and cognitive disorders
WO2002100836A2 (en) * 2001-06-12 2002-12-19 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
US20030191144A1 (en) * 2001-06-12 2003-10-09 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
EP1412045A4 (en) * 2001-06-25 2007-05-02 Lipid Sciences Inc A SOLVENT FOR REMOVING LIPIDES FROM FLUIDS USING SYSTEMS AND METHOD
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
EP1409108A4 (en) * 2001-06-25 2007-11-14 Lipid Sciences Inc HOLLOW FIBER CONTACTOR SYSTEMS FOR THE REMOVAL OF LIPIDS FROM LIQUIDS
US7033500B2 (en) * 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US20060060520A1 (en) * 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
CA2478184A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Drug combination therapy
US20050222122A1 (en) * 2002-04-02 2005-10-06 Sean Lilienfeld Statin therapy for enhancing cognitive maintenance
AU2003259188B2 (en) * 2002-07-19 2008-03-06 Aryx Therapeutics, Inc. Materials and methods for treating hypercholesterolemia
US20040106556A1 (en) * 2002-08-26 2004-06-03 Yanhong Zhu Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004082675A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
CA2531227A1 (en) * 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
WO2005079779A1 (en) * 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
US6960803B2 (en) * 2003-10-23 2005-11-01 Silicon Storage Technology, Inc. Landing pad for use as a contact to a conductive spacer
CA2548313A1 (en) * 2003-12-23 2005-07-14 Musc Foundation For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
ATE535614T1 (de) * 2003-12-30 2011-12-15 Kowa Co Screening-verfahren fuer gamma-sekretase- inhibitoren
US20070161700A1 (en) * 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
US20070166360A1 (en) * 2004-03-31 2007-07-19 Kowa Co., Ltd. External preparation
WO2005123955A2 (en) * 2004-06-09 2005-12-29 Children's Medical Center Corporation Methods and compositions for modifying gene regulation and dna damage in ageing
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
US8353184B2 (en) * 2005-01-21 2013-01-15 Sinox Company Ltd. Tamper indicating padlock
CA2609980C (en) * 2005-05-27 2015-10-13 Queen's University At Kingston Treatment of protein folding disorders
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008112887A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
ES2330184B1 (es) * 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
US20120157419A1 (en) 2009-02-02 2012-06-21 Tuvia Gilat Methods and compositions for treating alzheimer's disease
CN111094537A (zh) * 2017-09-08 2020-05-01 自然免疫制御技术研究组合 阿尔茨海默症诊断装置及方法
CA3083194A1 (en) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006470A1 (en) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
JP2001517617A (ja) * 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
JP2002501887A (ja) * 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US5252471A (en) * 1992-03-09 1993-10-12 Merck & Co., Inc. Directed biosynthesis of cholesterol lowering compounds
AU2401697A (en) * 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5703129A (en) * 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US5929062A (en) * 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006470A1 (en) * 1993-08-30 1995-03-09 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
JP2001517617A (ja) * 1997-09-24 2001-10-09 ノヴァ モレキュラー インク． 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法
JP2002501887A (ja) * 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NOTKOLA,I.L. ET AL: "Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease", NEUROEPIDEMIOLOGY, vol. 17, no. 1, JPN7009002741, 1998, pages 14 - 20, XP009086323, ISSN: 0001647737, DOI: 10.1159/000026149 *
SPARKS,D.L. ET AL: "Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary chol", EXP NEUROL, vol. 126, no. 1, JPN7009002740, 1994, pages 88 - 94, ISSN: 0001335813 *
SPARKS,D.L.: "Intraneuronal beta-amyloid immunoreactivity in the CNS", NEUROBIOL AGING, vol. 17, no. 2, JPN6009026690, 1996, pages 291 - 9, XP002117063, ISSN: 0001335814, DOI: 10.1016/0197-4580(95)02067-5 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150107938A (ko) * 2014-03-13 2015-09-24 주식회사 하이폭시 차전자피를 포함하는 기억력 및 인지기능 증진용 조성물
KR102287877B1 (ko) * 2014-03-13 2021-08-11 주식회사 하이폭시 차전자피를 포함하는 기억력 및 인지기능 증진용 조성물

Also Published As

Publication number Publication date
CA2324999A1 (en) 1999-09-30
US20020081263A1 (en) 2002-06-27
US6440387B1 (en) 2002-08-27
WO1999048488A3 (en) 2000-06-22
JP2010047616A (ja) 2010-03-04
US20020120003A1 (en) 2002-08-29
AU3200999A (en) 1999-10-18
US20060025469A1 (en) 2006-02-02
WO1999048488A2 (en) 1999-09-30
AU759257B2 (en) 2003-04-10
EP1063980A2 (en) 2001-01-03
US6080778A (en) 2000-06-27
US20020183379A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
US6080778A (en) Methods for decreasing beta amyloid protein
US6274603B1 (en) Methods for increasing ApoE levels for the treatment of neurodegenerative disease
Toledo et al. CSF Apo-E levels associate with cognitive decline and MRI changes
Duffau et al. Intraoperative unmasking of brain redundant motor sites during resection of a precentral angioma: evidence using direct cortical stimulation
M. Johnston et al. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential
Guerrini et al. A nonsense mutation of the ATRX gene causing mild mental retardation and epilepsy
Lauria et al. Clinical and magnetic resonance imaging findings in chronic sensory ganglionopathies
Tsimihodimos et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values
Ishii et al. Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans
CN1130200C (zh) 用于治疗痴呆的糖皮质激素受体拮抗剂
Kuriyama et al. Low levels of serum apolipoprotein AI and AII in senile dementia
Brod et al. Combination therapy with glatiramer acetate (copolymer‐1) and a type I interferon (IFN‐α) does not improve experimental autoimmune encephalomyelitis
Bates et al. Association of cardiovascular factors and Alzheimer's disease plasma amyloid-β protein in subjective memory complainers
Wood et al. Is hypercholesterolemia a risk factor for Alzheimer’s disease?
Numakura et al. Hemizygous mutation of the peripheral myelin protein 22 gene associated with Charcot‐Marie‐Tooth disease type 1
Bičíková et al. Plasma levels of 7-hydroxylated dehydroepiandrosterone (DHEA) metabolites and selected amino-thiols as discriminatory tools of Alzheimer's disease and vascular dementia.
AU2003200877B2 (en) Methods for decreasing beta amyloid protein
Tei et al. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer’s disease
Nilsson et al. Plasma homocysteine and vascular disease in psychogeriatric patients
CN120076808A (zh) 减少与神经退行性疾病相关的神经退行性变的方法
Graf et al. Diffusion‐weighted magnetic resonance imaging in boys with neural cell adhesion molecule L1 mutations and congenital hydrocephalus
Zheng et al. Statin is associated with higher cortical thickness in early Alzheimer's disease
Itoh et al. Endothelin‐1 in the brain of patients with galactosialidosis: Its abnormal increase and distribution pattern
Mehta et al. Increased serum neopterin levels in adults with Down syndrome
Baumgartner et al. Atypical Refsum disease with pipecolic acidemia and abnormal catalase distribution

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110105